A securities class action has been filed against Novo Nordisk A/S (NVO) on behalf of all investors who purchased or otherwise acquired Novo securities between May 7, 2025 through July 28, 2025. This case has been filed in the USDC – NJ.
On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025, citing the impact of increased competition in the markets for its drugs Ozempic and Wegovy. On this news, Novo Nordisk’s American Depository Receipt (“ADR”) price fell $15.06 per ADR, or 21.83%, to close at $53.94 per ADR on July 29, 2025.
The complaint alleges that during the Class Period, Defendants made materially false and misleading statements and engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Novo’s common stock and operated as a fraud or deceit on Class Period purchasers of Novo’s common stock by materially misleading the investing public. Later, Defendants’ prior misrepresentations and fraudulent conduct became apparent to the market, the price of Novo’s common stock materially declined, as the prior artificial inflation came out of the price over time. As a result of their purchases of Novo’s common stock during the Class Period.